Site icon pharmaceutical daily

Biologic API CDMO Benchmarking for New & Emerging Biopharma: Increased Investment and Presence of Start-Ups Galvanizes Sector – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biologic API CDMO Benchmarking for New & Emerging Biopharma” report has been added to ResearchAndMarkets.com’s offering.

Biological drugs have transformed the practice of medicine in a relatively short period of time, encouraging investment and an increase of start-ups focused on biologics. This report takes a closer look at the new and emerging biopharma landscape within the biologics space. This analysis will help new and emerging biopharma companies make more informed CMO decisions, and help CMOs optimize operational and marketing strategies to better accommodate this segment.

The publisher understands the need for a deeper dive regarding the new and emerging biopharma landscape. This report provides pharmaceutical companies and contract manufacturers comprehensive analysis of current outsourcing trends and practices, CMO selection drivers, and CMO perceptions and interactions specific to the new and emerging audience. Findings are based on 119 service encounters from 45 respondents who have been involved in outsourced large molecule API projects in the past 18 months.

What you will learn:

New and Emerging Drug Developers:

Contract Manufacturers:

Major Topics:

Key Topics Covered:

Copyright and Usage Guidelines

How to Use this Report

Analysis Note: Outsourcing Requirement

Introduction

Methodology

Respondent Demographics and Qualifications

Major Sections

Outsourcing Philosophies and Practices

CMO Selection Drivers

CMO Perceptions and Interactions

Study Data

Demographics

For more information about this report visit https://www.researchandmarkets.com/r/qigsa5

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version